Incyte Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INCY Nasdaq 2836 www.incyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incyte Corporation

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story - Nov 4th, 2026 2:06 pm
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 - Nov 4th, 2026 7:00 am
Incyte to Present at Upcoming Investor Conferences - Nov 4th, 2026 6:00 am
What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline? - Oct 31st, 2026 4:09 pm
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins - Oct 31st, 2026 1:15 am
Reddit downgraded, Rivian upgraded: Wall Street's top analyst calls - Oct 30th, 2026 7:45 am
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. Intel, Reddit, Rivian Automotive, and More - Oct 30th, 2026 6:14 am
Incyte Corporation Q3 2026 Earnings Call Summary - Oct 29th, 2026 7:35 pm
Incyte (INCY) Q3 2026 Earnings Call Transcript - Oct 29th, 2026 4:45 pm
What Incyte (INCY) Said on Its Q3 Earnings Call - Oct 29th, 2026 12:14 pm
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Oct 29th, 2026 12:11 pm
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say - Oct 29th, 2026 6:30 am
Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly - Oct 29th, 2026 5:45 am
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates - Oct 29th, 2026 5:35 am
Incyte: Q3 Earnings Snapshot - Oct 29th, 2026 5:09 am
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates - Oct 29th, 2026 5:00 am
Incyte (INCY) reports Q3: everything you need to know ahead of earnings - Oct 28th, 2026 8:14 am
What Would Slower New Drug Sales Do To Vertex Stock? - Oct 28th, 2026 6:01 am
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Oct 28th, 2026 5:00 am